Long term tenofovir disoproxil fumarate (TDF) therapy and the risk of hepatocellular carcinoma

被引：0

作者：

Sievert, W. ^{[1
,2
]}

Strasser, S. ^{[3
]}

Gane, E. ^{[4
]}

George, J. ^{[5
]}

Weilert, F. ^{[6
]}

Flaherty, J. F. ^{[7
]}

Dinh, P. ^{[7
]}

Schall, R. A. ^{[7
]}

Martins, E. B. ^{[7
]}

Yee, L. ^{[7
]}

Marcellin, P. ^{[8
]}

Kim, W. R. ^{[9
]}

机构：

[1] Monash Univ, Melbourne, Vic 3004, Australia

[2] Monash Med Ctr, Melbourne, Vic, Australia

[3] Royal Prince Alfred Hosp, Sydney, NSW, Australia

[4] Auckland City Hosp, Auckland, New Zealand

[5] Univ Sydney, Westmead Hosp, Storr Liver Unit, Sydney, NSW 2006, Australia

[6] Waikato Hosp, Hamilton, New Zealand

[7] Gilead Sci Inc, Foster City, CA 94404 USA

[8] Hop Beaujon, Clichy, France

[9] Mayo Clin, Rochester, MN USA

来源：

JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY | 2013年 / 28卷

关键词：

D O I：

暂无

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

引用

页码：53 / 54

页数：2

共 50 条

[31] Switching Tenofovir Disoproxil Fumarate (TDF) to Tenofovir Alafenamide Fumarate (TAF) in Hepatitis B/HIV Co-Infection: A Feasibility Study
Lok, James
Veloz, Maria Fernanda Guerra
Byrne, Ruth
Carey, Ivana
Childs, Kate
Agarwal, Kosh
Nelson, Mark
CLINICAL THERAPEUTICS, 2024, 46 (02) : 159 - 163
[32] Use of tenofovir disoproxil fumarate is associated with a lower risk of hepatocellular carcinoma than entecavir in patients with chronic hepatitis B
Choi, Won-Mook
Choi, Jonggi
HEPATOMA RESEARCH, 2021, 7
[33] Hepatocellular carcinoma and death and transplantation in chronic hepatitis B treated with entecavir or tenofovir disoproxil fumarate
Ha, Yeonjung
Chon, Young Eun
Kim, Mi Na
Lee, Joo Ho
Hwang, Seong Gyu
SCIENTIFIC REPORTS, 2020, 10 (01)
[34] Tenofovir disoproxil fumarate withdrawal and cardiovascular risk Reply
Neesgaard, Bastian
Greenberg, Lauren
Peters, Lars
Mocroft, Amanda
Ryom, Lene
Writing Grp
RESPOND Study Grp
LANCET HIV, 2023, 10 (01): : E9 - E10
[35] Efficacy of entecavir versus tenofovir disoproxil fumarate in preventing hepatocellular carcinoma-The jury is out
Peng, Cheng-Yuan
ADVANCES IN DIGESTIVE MEDICINE, 2024, 11 (01) : 5 - 7
[36] Hepatocellular carcinoma and death and transplantation in chronic hepatitis B treated with entecavir or tenofovir disoproxil fumarate
Yeonjung Ha
Young Eun Chon
Mi Na Kim
Joo Ho Lee
Seong Gyu Hwang
Scientific Reports, 10
[37] Is tenofovir disoproxil fumarate superior to entecavir for prevention of hepatocellular carcinoma in patients with chronic hepatitis B?
van Velsen, Lisa M.
Sonneveld, Milan J.
van Erpecum, Karel J.
HEPATOBILIARY SURGERY AND NUTRITION, 2023, 12 (06) : 919 - 922
[38] EFFICACY AND SAFETY OF TENOFOVIR ALAFENAMIDE (TAF) AT 96 WEEKS IN CHRONIC HBV (CHB) PATIENTS WITH RISK FACTORS FOR USE OF TENOFOVIR DISOPROXIL FUMARATE (TDF)
Chan, Henry Lik-Yuen
Buti, Maria
Flisiak, Robert
Ryder, Stephen
Streinu-Cercel, Adrian
Flaherty, John F.
Gaggar, Anuj
Mo, Shuyuan
Subramanian, G. Mani
Zoulim, Fabrian
Andreone, Pietro
Marcellin, Patrick
GUT, 2018, 67 : A97 - A97
[39] STUDY OF TRANSPORT OF TENOFOVIR AND TENOFOVIR DISOPROXIL FUMARATE ACROSS THE RAT TERM PLACENTA
Neumanova, Zuzana
Cerveny, Lukas
Staud, Frantisek
DRUG METABOLISM REVIEWS, 2014, 45 : 265 - 266
[40] 48-WEEK SAFETY AND EFFICACY OF SWITCHING TO TENOFOVIR ALAFENAMIDE (TAF) FROM TENOFOVIR DISOPROXIL FUMARATE (TDF) IN CHRONIC HBV ASIAN PATIENTS WITH TDF RISK FACTORS (RF)
Ahn, Sang Hoon
Kao, Jia-Horng
Hann, Hie-Won
Scott, Fung
Trinh, Huy
Nguyen, Tuan Trong
Paik, Seung Woon
Gaggar, Anuj
Flaherty, John
Yee, Leland
Jump, Belinda
Sethi, Shalini
Wu, George
Chan, Carol Yee Kwan
GUT, 2020, 69 : A73 - A74

← 1 2 3 4 5 →